

Mark LarchÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3084593/publications.pdf>

Version: 2024-02-01

155
papers

7,294
citations

71102

41
h-index

56724

83
g-index

159
all docs

159
docs citations

159
times ranked

4826
citing authors

#	ARTICLE	IF	CITATIONS
1	T cell-mediated autoimmunity in immune thrombocytopenia. <i>European Journal of Haematology</i> , 2022, 108, 18-27.	2.2	13
2	One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 454-468.	5.7	39
3	Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre- and post-peptide immunotherapy: An open-label clinical study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1907-1911.	5.7	4
4	Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2177-2188.	5.7	31
5	Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3589-3612.	5.7	23
6	Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections. <i>Viruses</i> , 2021, 13, 2239.	3.3	10
7	Increased cytotoxic potential of CD8 ⁺ T cells in immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 188, e72-e76.	2.5	11
8	Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1585-1597.	2.9	23
9	Induction of bystander tolerance and immune deviation after Fel d 1 peptide immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1087-1099.e4.	2.9	13
10	Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2157-2166.	5.7	25
11	Legends of allergy: Professor A. B. Kay. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1588-1590.	5.7	0
12	The Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): verification of nasal allergen challenge procedures in a study utilizing an investigational immunotherapy for cat allergy. <i>Clinical and Translational Allergy</i> , 2018, 8, 15.	3.2	13
13	Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1402-1412.	3.8	8
14	Perspectives in allergen immunotherapy: 2017 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 5-23.	5.7	76
15	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1035-1042.	5.7	85
16	Novel approaches and perspectives in allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1022-1034.	5.7	68
17	Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 486-496.	2.9	52
18	Investigating Immune Gene Signatures in Peripheral Blood from Subjects with Allergic Rhinitis Undergoing Nasal Allergen Challenge. <i>Journal of Immunology</i> , 2017, 199, 3395-3405.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Prediction of clinical peanut allergy status among children in Hamilton, Ontario using chart review data collected during 2012–2015. <i>Allergy, Asthma and Clinical Immunology</i> , 2017, 13, 10.	2.0	3
20	An Update on Lymphocyte Subtypes in Asthma and Airway Disease. <i>Chest</i> , 2017, 151, 1122-1130.	0.8	35
21	Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 283-285.	5.7	10
22	Ara h 1 Peptide Immunotherapy Protects Against Peanut-Induced Anaphylaxis in a Dose-Dependent Manner. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB410.	2.9	4
23	Epicutaneous Allergen Exposure Dose Determines Manifestation of Allergic Airway Disease in Mice. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB395.	2.9	1
24	Concepts and perspectives on peptide-based immunotherapy in allergy. <i>Allergo Journal</i> , 2016, 25, 22-31.	0.1	3
25	Concepts and perspectives on peptide-based immunotherapy in allergy. <i>Allergo Journal International</i> , 2016, 25, 144-153.	2.0	10
26	Fel d 1 Peptide Immunotherapy Ameliorates Both Cat and Ovalbumin Responses, in a Dual Allergen Murine Model of Allergic Airways Disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB64.	2.9	0
27	The Nasal Allergen Challenge Protocol of the Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): Validation in a Clinical Trial of Cat Synthetic Peptide Immunoregulatory Epitopes (Cat-SPIRE). <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB142.	2.9	2
28	Ara h 1 Peptide Immunotherapy Ameliorates Peanut-Induced Anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB158.	2.9	6
29	Initial Evidence of Sustained Efficacy of House Dust Mite Synthetic Peptide Immuno Regulatory Epitopes 2 Years after a Short Course of Treatment in House Dust Mite (HDM) Allergic Subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB142.	2.9	5
30	A Bell-Shaped Dose-Dependent Induction of Allergen-Specific Tetramer+ CD4 T Cells and Activated Lung ILC2s Following Epicutaneous Allergen Sensitization in HLA-DR4 Transgenic Mice. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB83.	2.9	1
31	The Contribution of Peptide-MHC Affinity to the Efficacy of Peptide Immunotherapy in a Murine Model of Allergic Airways Disease. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB243.	2.9	0
32	Persistent Treatment Effect with Grass Synthetic Peptide Immuno-Regulatory Epitopes in Grass Allergy Symptoms in an Environmental Exposure Unit Challenge after a Second Season of Natural Pollen Exposure. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB158.	2.9	10
33	Allergen immunotherapy on the way to product-based evaluation—a WAO statement. <i>World Allergy Organization Journal</i> , 2015, 8, 29.	3.5	70
34	T regulatory cell phenotypes in peripheral blood and bronchoalveolar lavage from non-asthmatic and asthmatic subjects. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1654-1662.	2.9	24
35	Peptide Immunotherapy; Short but Long Lasting?. <i>Current Treatment Options in Allergy</i> , 2015, 2, 64-71.	2.2	6
36	Fel d 1-derived synthetic peptide immunoregulatory epitopes show a long-term treatment effect in cat allergic subjects. <i>Clinical and Experimental Allergy</i> , 2015, 45, 974-981.	2.9	102

#	ARTICLE	IF	CITATIONS
37	Mechanisms of Peptide Immunotherapy in Allergic Airways Disease. <i>Annals of the American Thoracic Society</i> , 2014, 11, S292-S296.	3.2	33
38	T cell-mediated induction of thymic stromal lymphopoietin in differentiated human primary bronchial epithelial cells. <i>Clinical and Experimental Allergy</i> , 2014, 44, 953-964.	2.9	17
39	Treatment With Synthetic Peptide Immuno-Regulatory Epitopes Derived From Grass Allergens Leads To a Substantial Reduction In Grass Allergy Symptoms In The Environmental Exposure Unit. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB290.	2.9	6
40	Persistent Treatment Effect Achieved At One Year After Four Doses Of Der p Derived Synthetic Peptide Immuno-Regulatory Epitopes In An Exposure Chamber Model Of House Dust Mite Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB289.	2.9	14
41	Ex-Vivo Allergen Stimulation In Whole Blood: A Novel Approach For Evaluating Mechanisms Of Action Of Synthetic Peptide Immuno-Regulatory Epitopes. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB223.	2.9	0
42	Natural regulatory T cells in isolated early responders compared with dual responders with allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 696-703.	2.9	28
43	Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35. <i>Mucosal Immunology</i> , 2014, 7, 379-390.	6.0	19
44	Airway Tissue, But Not Luminal, Eosinophilia Is Related To The Magnitude Of Airway Hyperresponsiveness In a Transgenic Murine Model Of Cat Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB60.	2.9	0
45	Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes. <i>Clinical and Translational Allergy</i> , 2013, 3, O7.	3.2	6
46	Safety and Tolerability of Escalating Doses of House Dust Mite- Peptide Antigen Desensitization (HDM-PAD). <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB37.	2.9	18
47	Safety and Tolerability of Fel d 1-Derived Peptide Antigen Desensitization in Subjects with Controlled Asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB206.	2.9	2
48	Strategies to Query and Display Allergy-Derived Epitope Data From the Immune Epitope Database (IEDB). <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB209.	2.9	0
49	1. Two Year Persistent Treatment Effect Achieved After 4 Doses of Cat-Peptide Antigen Desensitization (Cat-PAD) in an Environmental Exposure Chamber (EEC) Model of Cat Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB147.	2.9	6
50	New Directions in Immunotherapy. <i>Current Allergy and Asthma Reports</i> , 2013, 13, 178-195.	5.3	54
51	Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 103-109.e7.	2.9	184
52	Strategies to Query and Display Allergy-Derived Epitope Data from the Immune Epitope Database. <i>International Archives of Allergy and Immunology</i> , 2013, 160, 334-345.	2.1	16
53	Cytokine responses of peripheral blood mononuclear cells to allergen do not identify asthma or asthma phenotypes. <i>Clinical and Experimental Allergy</i> , 2013, 43, 1226-1235.	2.9	10
54	Suppression of Allergic Airway Inflammation by Low Dose, Intranasally Administered Der p 1 Derived Peptides, in a Murine Model of House Dust Mite Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, AB241.	2.9	0

#	ARTICLE	IF	CITATIONS
55	Persistent Treatment Effect Achieved at One Year After 4 Doses of Fel d 1-Derived Peptide Immunotherapy in an Environmental Exposure Chamber (EEC) Model of Cat Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, AB144.	2.9	0
56	Functional rather than immunoreactive levels of IgG ₄ correlate closely with clinical response to grass pollen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 217-226.	5.7	254
57	Persistent Impairments in Humoral and Cellular Immunity in Patients with Immune Thrombocytopenia Treated with Rituximab: A Sub-Study of a Randomized Controlled Trial. <i>Blood</i> , 2012, 120, 492-492.	1.4	0
58	Peptide and Recombinant Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 377-389.	1.9	9
59	Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 89-97.e14.	2.9	159
60	Induction of Thymic Stromal Lymphopoietin (TSLP) in Airway Epithelium by Recombinant Allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, AB125-AB125.	2.9	2
61	Development and Preliminary Clinical Evaluation of a Peptide Immunotherapy Vaccine for Cat Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, AB219-AB219.	2.9	0
62	T Lymphocyte Responses to Nonpolymorphic HLA-Derived Peptides Are Associated With Chronic Renal Allograft Dysfunction. <i>Transplantation</i> , 2011, 91, 279-286.	1.0	12
63	Immunotherapy with peptides. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 784-791.	5.7	82
64	T Cell Epitope-Based Allergy Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2011, 352, 107-119.	1.1	41
65	Chronic Graft Versus Host Disease Is Associated With an Immune Response to Autologous Human Leukocyte Antigen-Derived Peptides. <i>Transplantation</i> , 2010, 90, 555-563.	1.0	3
66	Peptide-Based Therapeutic Vaccines for Allergic Diseases: Where Do We Stand?. , 2010, , 79-90.		0
67	Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. <i>Journal of Experimental Medicine</i> , 2009, 206, 1535-1547.	8.5	192
68	Of cats and men: immunodominance and the role of HLA-DP/DQ. <i>Clinical and Experimental Allergy</i> , 2008, 38, 1709-1711.	2.9	6
69	Determining MHC Restriction of T-cell Responses. <i>Methods in Molecular Medicine</i> , 2008, 138, 57-72.	0.8	3
70	Airway hyperresponsiveness and bronchial mucosal inflammation in T cell peptide-induced asthmatic reactions in atopic subjects. <i>Thorax</i> , 2007, 62, 750-757.	5.6	22
71	Regulatory T Cells in Allergy and Asthma. <i>Chest</i> , 2007, 132, 1007-1014.	0.8	178
72	Update on the current status of peptide immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 906-909.	2.9	93

#	ARTICLE	IF	CITATIONS
73	Immunotherapy with Allergen Peptides. <i>Allergy, Asthma and Clinical Immunology</i> , 2007, 3, 53.	2.0	18
74	Peptide immunotherapy for allergic diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 325-331.	5.7	65
75	Airway expression of calcitonin gene-related peptide in T-cell peptide-induced late asthmatic reactions in atopics. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 495-503.	5.7	41
76	Indirect Recognition of T-Cell Epitopes Derived from the β 3 and Transmembrane Domain of HLA-A2. <i>American Journal of Transplantation</i> , 2007, 7, 1148-1157.	4.7	19
77	Immunotherapy with Allergen Peptides. <i>Allergy, Asthma and Clinical Immunology</i> , 2007, 03, 53.	2.0	4
78	Peptide Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 321-332.	1.9	14
79	Peptide Immunotherapy in Fel d 1-Sensitized HLA-DR1 Transgenic Mice is Associated with Increased IL-10 but Independent of TGFbeta and Foxp3 Expression. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, S327.	2.9	0
80	Validation of a Functional Assay of IgE-Facilitated CD23-Dependent Allergen Binding to B Cells to Monitor Clinical Efficacy of Immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, S330.	2.9	1
81	Airway Expression of Calcitonin Gene-Related Peptide in T-Cell Peptide-Induced Late Asthmatic Reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, S188.	2.9	0
82	Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. <i>Clinical and Experimental Allergy</i> , 2006, 36, 465-474.	2.9	131
83	Immunological mechanisms of allergen-specific immunotherapy. <i>Nature Reviews Immunology</i> , 2006, 6, 761-771.	22.7	686
84	Immunoregulation by targeting T cells in the treatment of allergy and asthma. <i>Current Opinion in Immunology</i> , 2006, 18, 745-750.	5.5	58
85	The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. <i>Journal of Immunological Methods</i> , 2006, 317, 71-79.	1.4	138
86	Peptide-based vaccination: where do we stand?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2005, 5, 537-543.	2.3	32
87	Continuing Medical Education: an international reality. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 739-742.	5.7	3
88	The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 1269-1274.	5.7	117
89	Fel d 1-derived T cell peptide therapy induces recruitment of CD4 ⁺ CD25 ⁺ ; CD4 ⁺ interferon- γ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. <i>Clinical and Experimental Allergy</i> , 2005, 35, 52-58.	2.9	101
90	Peptide-based therapeutic vaccines for allergic and autoimmune diseases. <i>Nature Medicine</i> , 2005, 11, S69-S76.	30.7	290

#	ARTICLE	IF	CITATIONS
91	Peptide therapy for allergic diseases: Basic mechanisms and new clinical approaches. , 2005, 108, 353-361.		28
92	T Cell Epitope Immunotherapy Induces a CD4+ T Cell Population with Regulatory Activity. PLoS Medicine, 2005, 2, e78.	8.4	145
93	Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Review of Vaccines, 2005, 4, 881-889.	4.4	31
94	Late Asthmatic Reactions Induced by Inhalation of Allergen-derived T Cell Peptides. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 20-26.	5.6	69
95	Peptide Therapy and Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1331-1332.	5.6	2
96	Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 1097-1101.	5.7	72
97	The effects of T cell peptides in patients sensitive to cats. Clinical and Experimental Allergy Reviews, 2004, 4, 252-257.	0.3	1
98	Allergen immunotherapy with cat allergen peptides. Seminars in Immunopathology, 2004, 25, 391-399.	4.0	16
99	Investigating T cell activation and tolerance in vivo: peptide challenge in allergic asthmatics. Cytokine, 2004, 28, 49-54.	3.2	8
100	Tregs and allergic disease. Journal of Clinical Investigation, 2004, 114, 1389-1397.	8.2	235
101	Tregs and allergic disease. Journal of Clinical Investigation, 2004, 114, 1389-1397.	8.2	131
102	Late asthmatic reactions provoked by intradermal, but not inhaled, allergen-derived T-cell peptides induce "Tolerance" to subsequent antigen challenge. Journal of Allergy and Clinical Immunology, 2003, 111, S281.	2.9	2
103	Allergen-derived T cell peptides in immunotherapy. Revue Francaise D'allergologie Et D'immunologie Clinique, 2003, 43, 59-63.	0.1	1
104	The role of T lymphocytes in the pathogenesis of asthma. Journal of Allergy and Clinical Immunology, 2003, 111, 450-463.	2.9	521
105	Peptide immunotherapy for allergic disease. Expert Opinion on Biological Therapy, 2003, 3, 617-626.	3.1	10
106	Peptide-based immunotherapy: new developments. Arbeiten Aus Dem Paul-Ehrlich-Institut (Bundesamt) Tj ETQq0 0,0 rgBT /Oyerlock 10	0,0	2
107	Anti-IgE therapy combined with SIT: contra. Arbeiten Aus Dem Paul-Ehrlich-Institut (Bundesamt FÄ¼r) Tj ETQq1 1 0,784314 rgBT /Oyerlock 10	0,0	8
108	Inhalation of allergen-derived T cell peptide epitopes induces isolated late asthmatic reactions with associated local eosinophilia. Journal of Allergy and Clinical Immunology, 2002, 109, S167-S167.	2.9	3

#	ARTICLE	IF	CITATIONS
109	Desensitization (â€œToleranceâ€) induced by allergen-derived T cell peptide epitopes: Evidence for the induction of linked suppression. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S261-S261.	2.9	2
110	Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. <i>Lancet, The</i> , 2002, 360, 47-53.	13.7	353
111	T cell peptide epitope immunotherapy is accompanied by local increases in CD25+T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S362-S362.	2.9	3
112	The potential of peptide immunotherapy in allergy and asthma. <i>Current Allergy and Asthma Reports</i> , 2002, 2, 151-158.	5.3	10
113	Antiâ€Tâ€cell strategies in the treatment of allergic disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2002, 57, 20-23.	5.7	7
114	Methods for Identifying Human Eosinophils in Blood and Tissue. <i>Allergy and Clinical Immunology International</i> , 2002, 14, 0064-0071.	0.3	9
115	Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or TH2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 394-401.	2.9	59
116	Proliferation and release of IL-5 and IFN-Î³ by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, nonâ€cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 349-356.	2.9	35
117	The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. <i>European Respiratory Journal</i> , 2001, 18, 45-52.	6.7	57
118	Inhibition of human T-cell responses by allergen peptides. <i>Immunology</i> , 2001, 104, 377-382.	4.4	19
119	Mechanisms of T Cell Peptide Epitope-Dependent Late Asthmatic Reactions. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 272-275.	2.1	11
120	Allergen-Derived T Cell Peptide-Induced Late Asthmatic Reactions Precede the Induction of Antigen-Specific Hyporesponsiveness in Atopic Allergic Asthmatic Subjects. <i>Journal of Immunology</i> , 2001, 167, 1734-1739.	0.8	171
121	Changes in interferon-Î³ production following specific allergen immunotherapy: biology vs methodology. <i>Clinical and Experimental Allergy</i> , 2000, 30, 297-300.	2.9	5
122	Specific immunotherapy. <i>British Medical Bulletin</i> , 2000, 56, 1019-1036.	6.9	19
123	Peptide-Mediated Immune Responses in Specific Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 2000, 122, 229-237.	2.1	61
124	111 Attenuation of late cutaneous and asthmatic reactions following administration of short allergen-derived T cell peptide epitopes. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, S380.	2.9	1
125	Blood eosinophils from atopic donors express messenger RNA for the Î±, Î², and Î³ subunits of the high-affinity IgE receptor (FcÎ¼RI) and intracellular, but not cell surface, Î± subunit protein. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, 309-317.	2.9	44
126	468 Induction of cutaneous and bronchial hyporesponsiveness by short allergen-derived peptides. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, S154.	2.9	0

#	ARTICLE	IF	CITATIONS
127	752 Blood eosinophils from atopic donors express messenger RNA for the α , β , γ , and δ subunits of the high affinity IgE receptor (Fc ϵ R1) and intracellular, but not cell surface, α subunit protein. Journal of Allergy and Clinical Immunology, 2000, 105, S253.	2.9	0
128	753 Some pitfalls in measuring human eosinophil numbers in blood and tissues. Journal of Allergy and Clinical Immunology, 2000, 105, S253.	2.9	0
129	825 Mechanisms of the late asthmatic reaction induced by IgE-independent MHC-restricted T cell peptide epitopes. Journal of Allergy and Clinical Immunology, 2000, 105, S281.	2.9	0
130	MHC-restricted, IgE-independent, allergen peptide-induced late asthmatic reactions. Chemical Immunology and Allergy, 2000, 78, 30-8.	1.7	0
131	Immunoglobulin E ϵ -independent Major Histocompatibility Complex ϵ -restricted T Cell Peptide Epitope ϵ -induced Late Asthmatic Reactions. Journal of Experimental Medicine, 1999, 189, 1885-1894.	8.5	328
132	Allergen isoforms for immunotherapy: diversity, degeneracy and promiscuity. Clinical and Experimental Allergy, 1999, 29, 1588-1590.	2.9	3
133	Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. Journal of Immunology, 1998, 161, 6375-82.	0.8	72
134	IL-5 secretion by allergen-stimulated CD4+ T cells in primary culture: Relationship to expression of allergic disease. Journal of Allergy and Clinical Immunology, 1997, 99, 563-569.	2.9	118
135	T-cell responses to house dust mites: bad news for immunotherapy?. Clinical and Experimental Allergy, 1997, 27, 853-855.	2.9	0
136	Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. Journal of Immunology, 1997, 158, 3539-44.	0.8	273
137	Enhanced In Vivo Immunogenicity Induced by an Antibody to the IL-4 Receptor-Associated gp200-MR6 Molecule. Scandinavian Journal of Immunology, 1996, 44, 135-142.	2.7	5
138	A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome.. Journal of Clinical Investigation, 1996, 97, 196-201.	8.2	36
139	Inhibition of alloreactivity by mAb MR6: differential effects on IL-2- and IL-4-producing human T cells. International Immunology, 1994, 6, 1575-1584.	4.0	22
140	Immunological Events Underlying the Induction of T Cell Non-Responsiveness. International Archives of Allergy and Immunology, 1994, 104, 211-215.	2.1	5
141	Hyper IgM syndrome associated with defective CD40-mediated B cell activation.. Journal of Clinical Investigation, 1994, 94, 1404-1409.	8.2	81
142	Fetal thymocyte potential for T cell receptor V β 3-J β 31 junctional modification. European Journal of Immunology, 1993, 23, 1328-1332.	2.9	6
143	TNF Receptor Involvement in TNF-Mediated Activities against Syngeneic Malignant and Normal Mouse Thymocytes. Cellular Immunology, 1993, 152, 510-521.	3.0	3
144	Restricted usage of T-cell receptor V β sequence and variable-joining pairs after normal T-cell development and bone marrow transplantation. Human Immunology, 1993, 37, 178-184.	2.4	6

#	ARTICLE	IF	CITATIONS
145	Diversity of T-cell receptor alpha gene transcripts in the newborn and adult periphery. Immunogenetics, 1992, 36, 95-103.	2.4	19
146	Environmental influence on T cell receptor $\hat{\alpha}$ gene rearrangement and expression in vitro. European Journal of Immunology, 1992, 22, 2733-2736.	2.9	12
147	The effects of blockade of interleukin 2 receptors and interleukin 4 receptors on cytokine production. Apmis, 1991, 99, 434-442.	2.0	9
148	Developmental T cell receptor gene rearrangements: Relatedness of the $\hat{\alpha}^{\pm}/\hat{\beta}^2$ and $\hat{\alpha}^3/\hat{\beta}^1$ T cell precursor. European Journal of Immunology, 1991, 21, 1939-1950.	2.9	38
149	Environmental and allele-specific influences on T cell receptor gene rearrangement: skewed $\hat{\alpha}^{\pm}$, $\hat{\alpha}^1$ and $\hat{\alpha}^3$ gene rearrangement patterns in chimeric mice. European Journal of Immunology, 1991, 21, 2943-2949.	2.9	10
150	Tumour-associated upregulation of the IL-4 receptor complex. The British Journal of Cancer Supplement, 1990, 10, 96-8.	0.1	8
151	Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?. British Journal of Cancer, 1989, 59, 910-914.	6.4	26
152	T and B cell ontogeny and phylogeny. Current Opinion in Immunology, 1988, 1, 203-209.	5.5	2
153	Myasthenia gravis thymus: Clinical, histological and culture correlations. Journal of Autoimmunity, 1988, 1, 445-467.	6.5	46
154	A novel T-lymphocyte molecule that may function in the induction of self-tolerance and MHC-restriction within the human thymic microenvironment. Immunology, 1988, 64, 101-5.	4.4	18
155	Functional evidence for a monoclonal antibody that binds to the human IL-4 receptor. Immunology, 1988, 65, 617-22.	4.4	26